Wednesday, October 14, 2026

Stellar Trading Systems Links AI Infrastructure to Seven Commodity Exchanges in Five-Month Push

Stellar Trading Systems connected its automated trading platform to seven major commodity exchanges between July and November 2025, ending with Abaxx Exchange integration on November 30. The fintech firm deployed four AI-powered products—Quantum Server, MarketMaker, spreadMachine, and Server API—across exchanges handling gold, oil, and agricultural futures in Singapore, Dubai, India, Thailand, Japan, and China.

Stellar Trading Systems Links AI Infrastructure to Seven Commodity Exchanges in Five-Month Push
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Stellar Trading Systems completed connectivity integration with Abaxx Exchange on November 30, 2025, capping a five-month expansion that linked its AI trading infrastructure to seven commodity exchanges across Asia and the Middle East.

The fintech provider now operates on Thailand Futures Exchange, Dubai Gold and Commodities Exchange, Multi Commodity Exchange of India, Comex, Shanghai Futures Exchange, Tokyo Commodity Exchange, and Abaxx. Each integration supports four automated trading products: Quantum Server for execution, MarketMaker for liquidity provision, spreadMachine for arbitrage strategies, and Server API for custom algorithm deployment.

Abaxx launched USD-denominated gold futures contracts in November, backed by Singapore-based Abaxx Spot for physical settlement. The exchange targets institutional traders seeking alternatives to traditional London and New York gold markets. Stellar's connection provides algorithmic trading access from day one, unlike legacy commodity exchanges that added electronic trading infrastructure years after launch.

The integration pattern follows Stellar's deployment model: connect core trading engine first, then roll out specialized products within 60-90 days. Thailand Futures Exchange received the full product suite in July. Dubai Gold and Commodities Exchange integration followed in August, with Multi Commodity Exchange of India and Shanghai Futures Exchange added in September.

LuniCapital, a cryptocurrency-focused algorithmic trading firm, stated its platform architecture was "designed to support real-time interaction with cryptocurrency markets" with "performance-led platform development as cryptocurrency markets evolve." The language mirrors Stellar's positioning for commodity markets, suggesting infrastructure providers see similar adoption curves across asset classes.

Commodity exchanges historically relied on open-outcry trading and manual order execution. CME Group took 12 years to fully transition Comex gold futures to electronic trading after launching Globex in 1992. Abaxx launched with electronic infrastructure and algorithmic connectivity simultaneously.

Trading volume data from exchanges post-integration will show whether AI-driven execution infrastructure accelerates algorithmic adoption rates. Thailand Futures Exchange and Dubai Gold and Commodities Exchange, with July and August connections, provide the earliest test cases for measuring automated trading growth against manual execution volumes.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com